



Press release

## Valbiotis expands its e-commerce to Belgium and Luxembourg

La Rochelle, April 23, 2026 (5:40 PM CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible), a French laboratory specializing in the development and distribution of scientifically tested dietary supplements designed to support health at every stage of life, **announces the expansion of its e-commerce delivery service to Belgium and Luxembourg.**

### Valbiotis strengthens its e-commerce logistics and opens delivery to Belgium and Luxembourg

Valbiotis has reached a new milestone in the development of its e-commerce business with the official launch of deliveries to Belgium and Luxembourg. This expansion strengthens Valbiotis' logistics architecture and supports the continued growth of its online commercial activity.

**Consumers residing in Belgium and Luxembourg can now access all Valbiotis solutions available online and benefit from a reliable delivery service adapted to their geographical area.** Customers access this service by registering an international delivery address when placing their order.

In keeping with its commitment to flexibility and customer care, Valbiotis offers several delivery options:

- **Delivery to pick-up points in France**, particularly suited to cross-border customers;
- **Home delivery in Belgium and Luxembourg**, provided by Colissimo International, a recognized logistics partner.

Through this expansion, Valbiotis continues to roll out its development strategy built on a high-performing logistics network, **ongoing attention to user experience**, and a commitment to **making clinically tested, high-quality solutions accessible to all for lasting health.**

#### Shareholder benefit

**20% off Valbiotis<sup>PRO</sup>® and Valbiotis<sup>PLUS</sup>® products**, granted by customer service ([service-client@valbiotis.com](mailto:service-client@valbiotis.com)) upon presentation of proof of ownership of at least 85 shares

Terms and Conditions: [Click here](#)

## About Valbiotis

Valbiotis is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis®, please visit: [www.valbiotis.com](http://www.valbiotis.com)

## Contacts

Corporate Communication / Valbiotis

**Caroline Lamberti**

+ 33 6 77 82 56 88

[caroline.lamberti@valbiotis.com](mailto:caroline.lamberti@valbiotis.com)

Financial communication / Seitosei.Actifin

**Marianne Py**

+33 6 85 52 76 93

[marianne.py@seitosei-actifin.com](mailto:marianne.py@seitosei-actifin.com)

Press Relations / LJ Com by JIN

**Valentine Martin**

+33 6 32 29 43 82

[v.martin@ljcom.net](mailto:v.martin@ljcom.net)



Name: Valbiotis

ISIN Code: FR0013254851

Ticker Symbol: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website ([www.valbiotis.com](http://www.valbiotis.com)). This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.